Leveraging the National Cancer Institute’s collaborative efforts to understand the benefits and harms of cannabis use among individuals with cancer

Cannabis use for symptom management among patients with cancer has increased significantly in recent years, with many reporting benefits for pain, anxiety, sleep, nausea, appetite as well as other symptoms. However, rigorous prospective data on the potential benefits and harms of cannabis use in this population are lacking. This Commentary describes a United States National Cancer Institute (NCI)-led initiative addressing this research gap by supporting five prospective observational studies evaluating the benefits and harms of cannabis use among a large, heterogeneous samples of patients with cancer undergoing active systemic treatment. We provide an overview of each study, including cancer type, treatment modalities, inclusion/exclusion criteria, data collection methods, and both patient-reported and cancer-related outcomes.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-02-24
DOI
https://doi.org/10.1093/jnci/djag057
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Leveraging the National Cancer Institute’s collaborative efforts to understand the benefits and harms of cannabis use among individuals with cancer

Alfonso Romero-Sandoval, Brooke K. Worster, Shannon M. Nugent, Reina Haque et al.
JNCI Journal of the National Cancer Institute
Cannabis and Cannabinoid Research
article

Leveraging the National Cancer Institute’s collaborative efforts to understand the benefits and harms of cannabis use among individuals with cancer

Alfonso Romero-Sandoval, Brooke K. Worster, Shannon M. Nugent, Reina Haque, Kelly K. Filipski, Rebecca L. Ashare, Richard T. Lee, Freedman An, Jennifer Cullen, Kimberly G Wagoner, Arnold L Potosky, Beth A Reboussin, Yan Wang
article en

Abstract

Cannabis use for symptom management among patients with cancer has increased significantly in recent years, with many reporting benefits for pain, anxiety, sleep, nausea, appetite as well as other symptoms. However, rigorous prospective data on the potential benefits and harms of cannabis use in this population are lacking. This Commentary describes a United States National Cancer Institute (NCI)-led initiative addressing this research gap by supporting five prospective observational studies evaluating the benefits and harms of cannabis use among a large, heterogeneous samples of patients with cancer undergoing active systemic treatment. We provide an overview of each study, including cancer type, treatment modalities, inclusion/exclusion criteria, data collection methods, and both patient-reported and cancer-related outcomes.

JNCI Journal of the National Cancer Institute
Buffalo State University (US), Houston Methodist (US), City Of Hope National Medical Center (US), Kaiser Permanente (US), Thomas Jefferson University (US), Oregon Health & Science University (US), Georgetown University (US), Georgetown University Medical Center (US), University of Florida Health (US), University of Florida (US), Neurobehavioral Systems (US), Sidney Kimmel Cancer Center (US), Methodist Hospital (US), National Cancer Institute (US), Sylvester Comprehensive Cancer Center (US), Wake Forest University (US), University at Buffalo, State University of New York (US)
Reduced inequalities
Openalex Percentile: Top 41%
Cannabis and Cannabinoid Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.